Business
IGC Pharma Reports 65% Patient Enrollment Milestone in Phase 2 CALMA Alzheimer's Agitation Trial
POTOMAC, MARYLAND / ACCESS Newswire / December 9, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company leveraging Artificial Intelligence (AI) to develop innovative treatments for Alzheimer's ...
About this update from Igc Pharma, Inc.
[{"type":"text","content":"POTOMAC, MARYLAND / ACCESS Newswire / December 9, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company leveraging Artificial Intelligence (AI) to develop innovative treatments for Alzheimer's disease, today announced it has reached a key enrollment milestone of 65% for its ongoing Phase 2 CALMA clinical trial evaluating IGC-AD1 for the treatment of agitation in Alzheimer's disease.","length":468,"tagName":"p"},{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":"IGC Pharma, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":1504,"height":890,"url":"https://media.zenfs.com/en/accesswire.ca/b4e7ba7ce95ab1db080e5b2fcfc841f6"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ZO0f9HFpnSoQRCkLdtr3SQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTU2ODtjZj13ZWJw/https://media.zenfs.com/en/accesswire.ca/b4e7ba7ce95ab1db080e5b2fcfc841f6","width":960,"height":568},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/uvGqolpY1W2xWW9DqGldJg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD0xNDIwO2NmPXdlYnA-/https://media.zenfs.com/en/accesswire.ca/b4e7ba7ce95ab1db080e5b2fcfc841f6","width":1200,"height":710}},"href":"https://app.accessnewswire.com/imagelibrary/668715f0-16ed-44c7-a689-ec5d086ea1c9/igc-pharma-inc-2025.png","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"This milestone marks a significant step in advancing IGC-AD1, the Company's proprietary formulation, and demonstrates continued strong momentum toward full enrollment consistent with the goal of completing the trial in early 2026.","length":234,"tagName":"p"},{"type":"text","content":"Enrollment has accelerated, meaningfully, supported by the Company's data-driven digital recruitment strategy. Approximately 25% of all participants enrolled to date were recruited through IGC Pharma's targeted social-media campaigns, while 75% were enrolled directly through clinical-site efforts.","length":306,"tagName":"p"},{"type":"text","content":""Our hybrid recruitment strategy combining site-driven outreach with precision digital campaigns has expanded patient access and accelerated enrollment. We remain focused on completing the trial efficiently, maintaining high data quality, and advancing IGC-AD1 as a potential new therapy for agitation in ...